<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112454890</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112454890</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cardioprotective effect of lycopene against isoproterenol-induced myocardial infarction in rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ojha</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112454890">1</xref>
<xref ref-type="corresp" rid="corresp1-0960327112454890"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goyal</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112454890">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sharma</surname>
<given-names>C</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112454890">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arora</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112454890">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kumari</surname>
<given-names>S</given-names>
</name>
<xref ref-type="aff" rid="aff3-0960327112454890">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Arya</surname>
<given-names>DS</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112454890">1</xref>
<xref ref-type="corresp" rid="corresp1-0960327112454890"/>
</contrib>
</contrib-group>
<aff id="aff1-0960327112454890">
<label>1</label>Cardiovascular Laboratory, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India</aff>
<aff id="aff2-0960327112454890">
<label>2</label>Department of Ocular Pharmacology, All India Institute of Medical Sciences, New Delhi, India</aff>
<aff id="aff3-0960327112454890">
<label>3</label>Division of Plant Physiology, Indian Agricultural Research Institute, New Delhi, India</aff>
<author-notes>
<corresp id="corresp1-0960327112454890">Shreesh Ojha and DS Arya, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-29, India. Email: <email>shreeshojha@gmail.com</email>; <email>dsarya16@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>32</volume>
<issue>5</issue>
<fpage>492</fpage>
<lpage>503</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The present study was designed to evaluate the cardioprotective potential of lycopene (LCP) against isoproterenol (ISP)-induced myocardial infarction (MI), by assessing hemodynamic, biochemical and histopathological parameters. Wistar male albino rats were orally administered with LCP (0.5, 1.0 and 1.5 mg/kg) or with vehicle for 30 days, with concurrent subcutaneous injections of ISP (85 mg/kg) on days 28 and 29. ISP significantly (<italic>p</italic> &lt; 0.05) decreased systolic, diastolic and mean arterial blood pressure (SAP, DAP and MAP, respectively) and heart rate (HR). ISP also decreased contractility (+LVdP/dt), relaxation (−LVdP/dt) and increased left ventricular end-diastolic pressure (LVEDP). In addition to functional impairment, ISP also caused a significant (<italic>p</italic> &lt; 0.05) decrease in antioxidants, namely, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSHPx), glutathione (GSH), cardiac injury marker enzymes, creatine phosphokinase-MB (CK-MB) and lactate dehydrogenase (LDH), as well as induced lipid peroxidation, malonaldialdehyde (MDA) and histopathological alterations in heart. However, pretreatment with LCP significantly (<italic>p</italic> &lt; 0.05) attenuated ISP-induced cardiac dysfunction as evidenced by improved SAP, DAP, MAP, HR, (±)LVdP/dt and reduced LVEDP. Pretreatment with LCP also significantly (<italic>p</italic> &lt; 0.05) prevented the depletion of antioxidants (SOD, CAT, GSHPx and GSH), myocyte injury marker enzymes (CK-MB and LDH) and inhibited lipid peroxidation and MDA formation in the heart. Furthermore, reduced necrosis, edema and infiltration of inflammatory cells on histopathological examination also depicted the protective effect of LCP against the deleterious effect of ISP. Based on the results, it is suggested that LCP possesses significant cardioprotective potential and may serve as an adjunct in treatment and prophylaxis of MI.</p>
</abstract>
<kwd-group>
<kwd>Carotenoid</kwd>
<kwd>lycopene</kwd>
<kwd>ischemic injury</kwd>
<kwd>oxidative stress</kwd>
<kwd>cardiac function</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112454890">
<title>Introduction</title>
<p>Myocardial infarction (MI) continues to be an immense health problem causing mortality and morbidity across the developing and developed countries despite improved clinical care and public awareness.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112454890">1</xref>
</sup> It occurs when there is insufficient blood supply to the myocardium leading death of cardiomyocytes, a condition known as ischemia. Prolonged ischemia of the myocardium leads to necrosis, which is usually followed by many pathophysiological, functional, biochemical and electrocardiographic changes. In ischemia, free radicals and reactive oxygen species (ROS) are the central components of cellular oxidative damage, which culpably affects the myocardium.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454890">2</xref>
</sup>
</p>
<p>Thus, a great deal of research is focused on the role of antioxidants in the prevention of many human diseases, particularly atherosclerosis, congestive heart failure and myocardial ischemia-reperfusion injury.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112454890">3</xref>,<xref ref-type="bibr" rid="bibr4-0960327112454890">4</xref>
</sup> Numerous epidemiological, clinical and experimental studies have shown that antioxidants may slow down the progression and consequences of MI.<sup>
<xref ref-type="bibr" rid="bibr5-0960327112454890">5</xref>
<xref ref-type="bibr" rid="bibr6-0960327112454890"/>–<xref ref-type="bibr" rid="bibr7-0960327112454890">7</xref>
</sup>
</p>
<p>In recent years, many nutrient- and non-nutrient-based natural antioxidants such as phytoestrogens in soy, epigallocatechin in green tea, anthocyanins in red berries, resveratrol in grape seeds and lycopene (LCP) in tomatoes are increasingly being recognized as potential health promoters in reducing the risk of cardiovascular diseases (CVDs).<sup>
<xref ref-type="bibr" rid="bibr8-0960327112454890">8</xref>
</sup> LCP is one of over 600 carotenoids found in tomato, pink grapefruit, guava, papaya and watermelons, which impart a characteristic red pigmentation. Since humans are unable to synthesize carotenoids de novo, they usually acquire it from the dietary intake.<sup>
<xref ref-type="bibr" rid="bibr9-0960327112454890">9</xref>
</sup> Chemically, LCP is a lipid soluble and highly unsaturated hydrocarbon containing 11 conjugated and 2 unconjugated double bonds, normally in the all-<italic>trans</italic> configuration (<xref ref-type="fig" rid="fig1-0960327112454890">Figure 1</xref>). It is an acyclic isomer of β-carotene.<sup>
<xref ref-type="bibr" rid="bibr10-0960327112454890">10</xref>
</sup> LCP has been shown protective against myocardial ischemic-reperfusion injury,<sup>
<xref ref-type="bibr" rid="bibr11-0960327112454890">11</xref>
</sup> doxorubicin-induced cardiotoxicity,<sup>
<xref ref-type="bibr" rid="bibr12-0960327112454890">12</xref>
</sup> cerebral ischemia<sup>
<xref ref-type="bibr" rid="bibr13-0960327112454890">13</xref>
</sup> and neurodegenerative diseases.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112454890">14</xref>
</sup>
</p>
<fig id="fig1-0960327112454890" position="float">
<label>Figure 1.</label>
<caption>
<p>Chemical structure of lycopene.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454890-fig1.tif"/>
</fig>
<p>Numerous epidemiological studies and supplementation human trials have shown an inverse relationship between the consumption of carotenoid rich diet and the risk of cancer and coronary heart diseases.<sup>
<xref ref-type="bibr" rid="bibr15-0960327112454890">15</xref>
<xref ref-type="bibr" rid="bibr16-0960327112454890"/>–<xref ref-type="bibr" rid="bibr17-0960327112454890">17</xref>
</sup> The reduction in CVD risk factors has been shown to be associated with dietary intake, serum or plasma concentrations and adipose tissue concentration of carotenoids. In a multicenter, case-control study, European Study of Antioxidants, Myocardial Infarction and Cancer of the Breast (EURAMIC), the foods rich in LCP has been found to reduce the risk of MI.<sup>
<xref ref-type="bibr" rid="bibr15-0960327112454890">15</xref>
</sup> In another study, a reduction in the intimal wall thickness and risk of MI has been reported in persons with higher adipose tissue concentrations of LCP.<sup>
<xref ref-type="bibr" rid="bibr16-0960327112454890">16</xref>
</sup> Despite the emerging evidences suggesting a causal–effect relationship on the possible role of LCP in the primary prevention of CVD, there is paucity of data on its role in myocardial ischemic injury.<sup>
<xref ref-type="bibr" rid="bibr15-0960327112454890">15</xref>
<xref ref-type="bibr" rid="bibr16-0960327112454890"/>
<xref ref-type="bibr" rid="bibr17-0960327112454890"/>
<xref ref-type="bibr" rid="bibr18-0960327112454890"/>–<xref ref-type="bibr" rid="bibr19-0960327112454890">19</xref>
</sup> Also, the mechanism of its protective action to substantiate its therapeutic efficacy still lacks significant data.</p>
<p>Isoproterenol (ISP), a synthetic catecholamine and β-adrenergic agonist, has been known to produce MI in rat heart owing to free radical generation due to auto-oxidation and positive inotropic and chronotropic effects.<sup>
<xref ref-type="bibr" rid="bibr20-0960327112454890">20</xref>,<xref ref-type="bibr" rid="bibr21-0960327112454890">21</xref>
</sup> Since pathophysiological, biochemical, morphological, functional alterations and histopathological lesions following ISP administration in rats are similar to those in human MI, the ISP-induced MI serves as a well-standardized model to study the beneficial effects and mechanism of many drugs.<sup>
<xref ref-type="bibr" rid="bibr22-0960327112454890">22</xref>,<xref ref-type="bibr" rid="bibr23-0960327112454890">23</xref>
</sup>
</p>
<p>Therefore, the aim of present study was to evaluate the cardioprotective potential of LCP in the experimental model of myocardial ischemic injury. ISP was used to produce MI in experimental rats and LCP was administered before and at the onset of ischemia. In order to demonstrate the mechanism of cardioprotection, the hemodynamic and ventricular function parameters and biochemical markers of myocardial injury as well as antioxidants and lipid peroxidation were assessed in heart. Further, histopathological studies were also incorporated to support the biochemical and hemodynamic effects of LCP.</p>
</sec>
<sec id="section2-0960327112454890" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0960327112454890">
<title>Drugs and chemicals</title>
<p>The antioxidant enzyme standards and ISP hemisulfate were obtained from Sigma Chemicals Company (St Louis, Missouri, USA). LCP was the generous gift by Jagsonpal Pharmaceuticals Limited (New Delhi, India). All chemicals used in the study were of analytical grade. Double distilled water was used for the biochemical estimations. The doses of LCP in the present study have been selected based on the previous reported literature.<sup>
<xref ref-type="bibr" rid="bibr11-0960327112454890">11</xref>
</sup>
</p>
</sec>
<sec id="section4-0960327112454890">
<title>Experimental animals</title>
<p>Laboratory bred, 10–12 weeks old, Wistar male albino rats, weighing 150–200 g were used in the study. The study protocol was reviewed and approved by the Institutional Animal Ethics Committee and conforms to the Committee for the Purpose of Control and Supervision on Experiments on Animals. Animals were obtained from the Central Animal House Facility of All India Institute of Medical Sciences, New Delhi, India. A minimum of four rats were housed in the polypropylene cages (with stainless steel grill top) lined with husk, renewed every 24 h at standard laboratory conditions, natural light and dark cycles (approximately 14 h light/10 h dark), humidity (55 ± 10%) and an ambient temperature of 25 ± 2°C. All experiments were performed between 9.00 a.m. and 16.00 p.m. to maintain the physiological relevance of the circadian variation in measuring cardiac function. The animals were fed with standard pellet diet (Ashirwad Industries Limited, Chandigarh, India) and tap water ad libitum.</p>
</sec>
<sec id="section5-0960327112454890">
<title>Induction of experimental MI</title>
<p>A standardized dose of ISP 85 mg/kg body weight was injected subcutaneously (s.c.) for two consecutive days, at 24 h interval to induce MI in rats.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112454890">19</xref>
</sup>
</p>
</sec>
<sec id="section6-0960327112454890">
<title>Experimental design</title>
<p>The animals were acclimatized 1 week before the experiments and randomly allocated into eight experimental groups, with each consisting 12 rats. Group I (Sham): rats were administered with the vehicle orally using intragastric tube for 30 days and on 28th and 29th day administered with saline (0.5 ml s.c.) at an interval of 24 h. Group II (ISP control): rats were administered with the vehicle orally using intragastric tube for 30 days and on 28th and 29th day administered with ISP (85 mg/kg s.c.) at an interval of 24 h. Groups III–V (LCP): rats were administered with LCP orally using intragastric tube for 30 days and on 28th and 29th day administered with saline (0.5 ml s.c.) at an interval of 24 h. Groups VI–VIII (LCP + ISP): rats were administered with LCP orally using intragastric tube for 30 days and on 28th and 29th day administered with ISP (85 mg/kg s.c.) at an interval of 24 h. Changes in the body weight of each rat have been recorded weekly.</p>
</sec>
<sec id="section7-0960327112454890">
<title>Surgical preparation and hemodynamic measurement</title>
<p>For all experimental groups, rats were anesthetized with pentobarbitone sodium (60 mg/kg, intraperitoneally). Atropine (0.1 mg/kg) was coadministered with the anesthetic to reduce bronchotracheal secretions and keep the heart rate (HR) elevated during surgery. Body temperature was monitored and maintained at 37°C throughout the experimental protocol. Tracheostomy was performed to ventilate rats with room air from a positive pressure ventilator (Inco, Ambala, India) using compressed air at a rate of 90 strokes/min and a tidal volume of 10 ml/kg. Ventilator setting and oxygen were adjusted to maintain arterial blood gas parameters within the physiological range.</p>
<p>Left jugular vein was cannulated with polyethylene tube for continuous infusion of 0.9% saline. Right carotid artery was cannulated and filled with heparinized saline and connected with CARDIOSYSCO-101 (Experimentria, Hungary) using a pressure transducer for the measurement of hemodynamic parameters, systolic, diastolic and mean arterial blood pressure (SAP, DAP and MAP, respectively) as well as HR. Left thoracotomy was performed at the fifth intercostal space and the heart was exposed for the measurement of left ventricular function. A wide bore (1.5 mm) sterile metal cannula connected to a pressure transducer (Gould Statham P23ID, USA) was inserted into the cavity of left ventricle from the posterior apical region of heart for recording left ventricular pressure dynamics; left ventricular end-diastolic pressure (LVEDP), a surrogate marker of preload, peak positive pressure development ((+)LVdP/dt: marker of myocardial contraction) and peak negative pressure development ((−)LVdP/dt: marker of myocardial relaxation) representing contractility and relaxation using Polygraph (Grass 7D, USA). After insertion of transducer, the heart was managed in its normal position in thorax. Thoracic cavity was covered with saline-soaked gauze to prevent heart from drying. Before recording the hemodynamic and ventricular function, animals were allowed to stabilize for 5 min and the hemodynamically unstable rats were excluded from the study. After recording hemodynamic and ventricular contractile function, animals were killed for biochemical and histological studies under the overdose of anesthesia.</p>
</sec>
<sec id="section8-0960327112454890">
<title>Biochemical estimations</title>
<p>All biochemical parameters were estimated in heart tissues. A 10% homogenate of heart was prepared in phosphate buffer (50 mM, pH 7.4), and aliquots of 0.5 ml were used for the estimation of reduced glutathione (GSH)<sup>
<xref ref-type="bibr" rid="bibr24-0960327112454890">24</xref>
</sup> and malondialdehyde (MDA).<sup>
<xref ref-type="bibr" rid="bibr25-0960327112454890">25</xref>
</sup> Remaining homogenate was centrifuged at 7000 r/min for 15 min and the obtained supernatant was used for the estimation of endogenous antioxidant enzymes, such as superoxide dismutase (SOD),<sup>
<xref ref-type="bibr" rid="bibr26-0960327112454890">26</xref>
</sup> catalase (CAT),<sup>
<xref ref-type="bibr" rid="bibr27-0960327112454890">27</xref>
</sup> glutathione peroxidase (GSHPx)<sup>
<xref ref-type="bibr" rid="bibr28-0960327112454890">28</xref>
</sup> and myocytes injury marker enzymes, as well as creatine phosphokinase-MB isoenzyme (CK-MB),<sup>
<xref ref-type="bibr" rid="bibr29-0960327112454890">29</xref>
</sup> lactate dehydrogenase (LDH)<sup>
<xref ref-type="bibr" rid="bibr30-0960327112454890">30</xref>
</sup> and protein.<sup>
<xref ref-type="bibr" rid="bibr31-0960327112454890">31</xref>
</sup>
</p>
</sec>
<sec id="section9-0960327112454890">
<title>Histological studies of myocardium</title>
<p>Myocardial tissue was immediately fixed in 10% formalin solution. The fixed tissues were embedded in paraffin and serial sections were cut. After hematoxylin and eosin staining, the sections were examined under light microscope (Nikon, Tokyo, Japan).</p>
</sec>
<sec id="section10-0960327112454890">
<title>Statistical analysis</title>
<p>All the data were analyzed using one-way analysis of variance with post hoc analysis and Bonferroni’s multiple range test. Mean and SD were calculated for biochemical and hemodynamic variables in each group. <italic>p</italic> &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section11-0960327112454890">
<title>Results</title>
<sec id="section12-0960327112454890">
<title>Mortality</title>
<p>A total of 96 rats were included in the study, and the data obtained for 84 rats were used in this study. The hemodynamically unstable (8.5%) rats were excluded from the study. The mortality rate of 4.4% was observed in the experimental period. The reasons for mortality and hemodynamic instability were blood loss during cannulation.</p>
</sec>
<sec id="section13-0960327112454890">
<title>Per se effect of LCP</title>
<p>LCP per se treatment (0.5, 1.0 and 1.5 mg/kg) did not show significant change on hemodynamic, biochemical and histopathology parameters when compared with Sham group.</p>
</sec>
<sec id="section14-0960327112454890">
<title>Effect of LCP on hemodynamic function</title>
<p>A significant decrease in SAP, DAP, MAP and HR was observed in ISP-control animals as compared to Sham group (<xref ref-type="table" rid="table1-0960327112454890">Table 1</xref>). Pretreatment with LCP at 1.0 and 1.5 mg/kg significantly restored arterial pressure such as SAP, DAP and MAP in ISP treated rats. However, LCP 0.5 mg/kg failed to improve arterial pressure. Along with restoration of arterial pressure, pretreatment with LCP at all doses (0.5, 1.0 and 1.5 mg/kg) significantly increased the HR compared with ISP control group.</p>
<table-wrap id="table1-0960327112454890" position="float">
<label>Table 1.</label>
<caption>
<p>Hemodynamic parameters in different experimental groups.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-0960327112454890" xlink:href="10.1177_0960327112454890-table1.tif"/>
<table>
<thead>
<tr>
<th>Groups (treatment)</th>
<th>SAP (mmHg)</th>
<th>DAP (mmHg)</th>
<th>MAP (mmHg)</th>
<th>HR (per min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (Sham; vehicle)</td>
<td>141 ± 24</td>
<td>127 ± 15</td>
<td>132 ± 18</td>
<td>359 ± 30</td>
</tr>
<tr>
<td>Group II (ISP control; vehicle + ISP)</td>
<td>87 ± 21<sup>b</sup>
</td>
<td>71 ± 12<sup>b</sup>
</td>
<td>76 ± 24<sup>b</sup>
</td>
<td>209 ± 39<sup>b</sup>
</td>
</tr>
<tr>
<td>Group III (LCP 0.5 mg/kg)</td>
<td>144 ± 22</td>
<td>123 ± 19</td>
<td>128 ± 19</td>
<td>360 ± 42</td>
</tr>
<tr>
<td>Group IV (LCP 1.0 mg/kg)</td>
<td>150 ± 20</td>
<td>126 ± 18</td>
<td>135 ± 25</td>
<td>350 ± 36</td>
</tr>
<tr>
<td>Group V (LCP 1.5 mg/kg)</td>
<td>148 ± 25</td>
<td>128 ± 24</td>
<td>136 ± 30</td>
<td>369 ± 41</td>
</tr>
<tr>
<td>Group VI (LCP 0.5 mg/kg + ISP) </td>
<td>100 ± 20</td>
<td>80 ± 18</td>
<td>89 ± 17</td>
<td>228 ± 32<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VII (LCP 1.0 mg/kg + ISP)</td>
<td>128 ± 21<sup>c</sup>
</td>
<td>113 ± 21<sup>c</sup>
</td>
<td>116 ± 27<sup>c</sup>
</td>
<td>295 ± 40<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VIII (LCP 1.5 mg/kg + ISP)</td>
<td>138 ± 18<sup>c</sup>
</td>
<td>120 ± 25<sup>c</sup>
</td>
<td>126 ± 23<sup>c</sup>
</td>
<td>320 ± 38<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112454890">
<p>LCP: lycopene; ISP: isoproterenol; SAP: systolic arterial blood pressure; DAP: diastolic arterial blood pressure; MAP: mean arterial blood pressure; HR: heart rate.</p>
</fn>
<fn id="table-fn2-0960327112454890">
<p>
<sup>a</sup>Values are mean ± SD (<italic>n</italic> = 6).</p>
</fn>
<fn id="table-fn3-0960327112454890">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.05 when compared with Sham.</p>
</fn>
<fn id="table-fn4-0960327112454890">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.05 when compared with ISP control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-0960327112454890">
<title>Effect of LCP on left ventricular contractile function</title>
<p>
<xref ref-type="fig" rid="fig2-0960327112454890">Figures 2</xref> and <xref ref-type="fig" rid="fig3-0960327112454890">3</xref> represent the alteration in left ventricular contractile function in different experimental groups. ISP-control rats showed left ventricular dysfunction as evidenced by significant decline in the values of (+)LVdP/dt and (−)LVdP/dt as compared to Sham group. However, ISP-induced decline in (+)LVdP/dt and (−)LVdP/dt was significantly prevented by pretreatment with LCP at all doses, except 0.5 mg/kg which failed to improve (+)LVdP/dt significantly in comparison with ISP control animals. In addition, a significant rise in LVEDP was also observed in ISP control animals as compared to Sham group (<xref ref-type="fig" rid="fig4-0960327112454890">Figure 4</xref>). LCP pretreatment at all doses (0.5–1.5 mg/kg) significantly decreased LVEDP when compared with ISP control group.</p>
<fig id="fig2-0960327112454890" position="float">
<label>Figure 2.</label>
<caption>
<p>Effect of LCP on the contractility; (+)LVdP/dt in different experimental groups. Values are mean ± SD (<italic>n</italic> = 6). <sup>*</sup>
<italic>p</italic> &lt; 0.05 when compared with Sham; <sup>#</sup>
<italic>p</italic> &lt; 0.05 when compared with ISP control. LCP: lycopene; (+)LVdP/dt: marker of myocardial contraction.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454890-fig2.tif"/>
</fig>
<fig id="fig3-0960327112454890" position="float">
<label>Figure 3.</label>
<caption>
<p>Effect of LCP on the relaxation; (−)LVdP/dt in different experimental groups. Values are mean ± SD (<italic>n</italic> = 6). <sup>*</sup>
<italic>p</italic> &lt; 0.05 when compared with Sham; <sup>#</sup>
<italic>p</italic> &lt; 0.05 when compared with ISP control. LCP: lycopene; (−)LVdP/dt: marker of myocardial relaxation.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454890-fig3.tif"/>
</fig>
<fig id="fig4-0960327112454890" position="float">
<label>Figure 4.</label>
<caption>
<p>Effect of LCP on the LVEDP in different experimental groups. Values are mean ± SD (<italic>n</italic> = 6). <sup>*</sup>
<italic>p</italic> &lt; 0.05 when compared with Sham; <sup>#</sup>
<italic>p</italic> &lt; 0.05 when compared with ISP control. LCP: lycopene; LVEDP: left ventricular end diastolic pressure; ISP: isoproterenol.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454890-fig4.tif"/>
</fig>
</sec>
<sec id="section16-0960327112454890">
<title>Effect of LCP on myocardial injury markers</title>
<p>ISP administration showed a significant decrease in the myocyte injury markers, CK-MB isoenzyme and LDH enzyme as compared to Sham group (<xref ref-type="table" rid="table2-0960327112454890">Table 2</xref>). However, LCP pretreatment at all doses (0.5, 1.0 and 1.5 mg/kg) significantly prevented the depletion of CK-MB and LDH enzymes from heart in comparison with ISP control group.</p>
<table-wrap id="table2-0960327112454890" position="float">
<label>Table 2.</label>
<caption>
<p>Myocytes injury marker enzymes in myocardium of different experimental groups.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0960327112454890" xlink:href="10.1177_0960327112454890-table2.tif"/>
<table>
<thead>
<tr>
<th>Groups (treatment)</th>
<th>CK-MB (IU/mg protein)</th>
<th>LDH (IU/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (Sham; vehicle)</td>
<td>167.97 ± 12.83</td>
<td>220.20 ± 16.74</td>
</tr>
<tr>
<td>Group II (ISP control; vehicle + ISP)</td>
<td>90.26 ± 12. 64<sup>b</sup>
</td>
<td>109.17 ± 11.28<sup>b</sup>
</td>
</tr>
<tr>
<td>Group III (LCP 0.5 mg/kg)</td>
<td>170.52 ± 18.16</td>
<td>209.42 ± 16.10</td>
</tr>
<tr>
<td>Group IV (LCP 1.0 mg/kg)</td>
<td>166.79 ± 17.76</td>
<td>217.60 ± 17.62</td>
</tr>
<tr>
<td>Group V (LCP 1.5 mg/kg)</td>
<td>169.35 ± 19.10</td>
<td>224.16 ± 13.29</td>
</tr>
<tr>
<td>Group VI (LCP 0.5 mg/kg + ISP) </td>
<td>148.64 ± 14.78<sup>c</sup>
</td>
<td>148.66 ± 14.34<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VII (LCP 1.0 mg/kg + ISP)</td>
<td>158.26 ± 15.35<sup>c</sup>
</td>
<td>181.75 ± 18.51<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VIII (LCP 1.5 mg/kg + ISP)</td>
<td>172.40 ± 18.52<sup>c</sup>
</td>
<td>201.23 ± 13.92<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0960327112454890">
<p>LCP: lycopene; ISP: isoproterenol; CK-MB: creatine phosphokinase-MB; LDH: lactate dehydrogenase.</p>
</fn>
<fn id="table-fn6-0960327112454890">
<p>
<sup>a</sup>Values are mean ± SD (<italic>n</italic> = 6).</p>
</fn>
<fn id="table-fn7-0960327112454890">
<p>
<sup>b</sup>
<italic> p</italic> &lt; 0.05 when compared with Sham.</p>
</fn>
<fn id="table-fn8-0960327112454890">
<p>
<sup>c</sup>
<italic> p</italic> &lt; 0.05 when compared with ISP control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section17-0960327112454890">
<title>Effect of LCP on reduced GSH and lipid peroxidation</title>
<p>In ISP-control group, a significant decrease in GSH content was observed in comparison with Sham group. Subsequent to the depletion of GSH, an increase in lipid peroxidation product, MDA was observed as compared to Sham group (<xref ref-type="table" rid="table3-0960327112454890">Table 3</xref>). LCP pretreatment at 1.0 and 1.5 mg/kg significantly prevented the depletion of GSH from heart and LCP at all doses (0.5, 1.0 and 1.5 mg/kg) inhibited lipid peroxidation as evidenced by reduced MDA levels, concomitant to increased GSH when compared with ISP-control animals. However, LCP 0.5 mg/kg did not show significant effect on the GSH.</p>
<table-wrap id="table3-0960327112454890" position="float">
<label>Table 3.</label>
<caption>
<p>Glutathione and lipid peroxidation in myocardium of different experimental groups.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0960327112454890" xlink:href="10.1177_0960327112454890-table3.tif"/>
<table>
<thead>
<tr>
<th>Groups (treatment)</th>
<th>GSH (µmol/g tissue protein)</th>
<th>MDA (nmol/g tissue protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (Sham; saline)</td>
<td>1.98 ± 0.76</td>
<td>70.95 ± 12.83</td>
</tr>
<tr>
<td>Group II (ISP control; vehicle + ISP)</td>
<td>0.84 ± 0.25<sup>b</sup>
</td>
<td>208.82 ± 10.71<sup>b</sup>
</td>
</tr>
<tr>
<td>Group III (LCP 0.5 mg/kg)</td>
<td>1.88 ± 0.97</td>
<td>68.30 ± 11.47</td>
</tr>
<tr>
<td>Group IV (LCP 1.0 mg/kg)</td>
<td>1.96 ± 1.03</td>
<td>72.54 ± 12.20</td>
</tr>
<tr>
<td>Group V (LCP 1.5 mg/kg)</td>
<td>2.03 ± 0.96</td>
<td>71.28 ± 15.33</td>
</tr>
<tr>
<td>Group VI (LCP 0.5 mg/kg + ISP)</td>
<td>1.02 ± 0.54</td>
<td>144.20 ± 10.09<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VII (LCP 1.0 mg/kg + ISP)</td>
<td>1.75 ± 0.91<sup>c</sup>
</td>
<td>117.54 ± 16.22<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VIII (LCP 1.5 mg/kg + ISP)</td>
<td>1.91 ± 0.50<sup>c</sup>
</td>
<td>96.48 ± 18.39<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0960327112454890">
<p>LCP: lycopene; ISP: isoproterenol; GSH: glutathione; MDA: malonaldialdehyde.</p>
</fn>
<fn id="table-fn10-0960327112454890">
<p>
<sup>a</sup>Values are mean ± SD (<italic>n</italic> = 6).</p>
</fn>
<fn id="table-fn11-0960327112454890">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.05, when compared to Sham.</p>
</fn>
<fn id="table-fn12-0960327112454890">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.05, when compared to ISP control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section18-0960327112454890">
<title>Effect of LCP on the activities of SOD, CAT and GSHPx enzymes</title>
<p>In ISP control group, a significant decrease in the values of SOD, CAT and GSHPx enzymes was observed as compared to Sham group (<xref ref-type="table" rid="table4-0960327112454890">Table 4</xref>). Pretreatment with LCP at all doses (0.5, 1.0 and 1.5 mg/kg) significantly prevented the decline of antioxidant enzymes in a dose-dependent manner when compared with ISP control group.</p>
<table-wrap id="table4-0960327112454890" position="float">
<label>Table 4.</label>
<caption>
<p>Antioxidant enzymes in myocardium of different experimental groups.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table4-0960327112454890" xlink:href="10.1177_0960327112454890-table4.tif"/>
<table>
<thead>
<tr>
<th>Groups (treatment)</th>
<th>SOD (U/mg protein)</th>
<th>CAT (U/mg protein)</th>
<th>GSHPx (U/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (Sham; vehicle) </td>
<td>8.21 ± 1.72</td>
<td>22.45 ± 2.16</td>
<td>1.04 ± 0.43</td>
</tr>
<tr>
<td>Group II (ISP control; vehicle + ISP)</td>
<td>3.45 ± 1.30<sup>b</sup>
</td>
<td>12.30 ± 1.83<sup>b</sup>
</td>
<td>0.48 ± 0.25<sup>b</sup>
</td>
</tr>
<tr>
<td>Group III (LCP 0.5 mg/kg) </td>
<td>8.52 ± 2.15</td>
<td>22.59 ± 1.97</td>
<td>0.98 ± 0.35</td>
</tr>
<tr>
<td>Group IV (LCP 1.0 mg/kg)</td>
<td>8.82 ± 2.10</td>
<td>22.95 ± 3.31</td>
<td>0.92 ± 0.41</td>
</tr>
<tr>
<td>Group V (LCP 1.5 mg/kg)</td>
<td>8.10 ± 2.04</td>
<td>23.83 ± 4.81</td>
<td>0.95 ± 0.38</td>
</tr>
<tr>
<td>Group VI (LCP 0.5 mg/kg + ISP) </td>
<td>7.15 ± 1.80<sup>c</sup>
</td>
<td>16.80 ± 2.65<sup>c</sup>
</td>
<td>0.67 ± 0.39<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VII (LCP 1.0 mg/kg + ISP)</td>
<td>7.95 ± 3.35<sup>c</sup>
</td>
<td>19.45 ± 3.23<sup>c</sup>
</td>
<td>0.78 ± 0.45<sup>c</sup>
</td>
</tr>
<tr>
<td>Group VIII (LCP 1.5 mg/kg + ISP)</td>
<td>8.18 ± 1.87<sup>c</sup>
</td>
<td>23.05 ± 4.27<sup>c</sup>
</td>
<td>0.95 ± 0.28<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn13-0960327112454890">
<p>LCP: lycopene; ISP: isoproterenol; SOD: superoxide dismutase; CAT: catalase; GSHPx: glutathione peroxidase.</p>
</fn>
<fn id="table-fn14-0960327112454890">
<p>
<sup>a</sup>Values are mean ± SD (<italic>n</italic> = 6).</p>
</fn>
<fn id="table-fn15-0960327112454890">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.05 when compared with Sham.</p>
</fn>
<fn id="table-fn16-0960327112454890">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.05 when compared with ISP control.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section19-0960327112454890">
<title>Effect of LCP on histopathological changes of rat myocardium</title>
<p>
<xref ref-type="fig" rid="fig5-0960327112454890">Figure 5(a)</xref> to (<xref ref-type="fig" rid="fig5-0960327112454890">e</xref>) shows the light micrograph of myocardium of rats in different experimental group. Histopathological changes were evaluated by a pathologist, All India Institute of Medical Sciences, New Delhi, who was masked to the treatments and biochemical results. The observations were graded and summarized in <xref ref-type="table" rid="table5-0960327112454890">Table 5</xref>. Sham group showed a normal myocardial histoarchitecture (<xref ref-type="fig" rid="fig5-0960327112454890">Figure 5(a)</xref>) and ISP-control group showed confluent necrosis of muscle fibers, edema and increased connective tissue among myocardial fibers along with extravasations of RBCs and infiltration of the inflammatory cells (<xref ref-type="fig" rid="fig5-0960327112454890">Figure 5(b)</xref>). LCP (0.5, 1.0 and 1.5 mg/kg) per se did not produce histopathological alterations in the myocardium. Rats pretreated with LCP 0.5 mg/kg, showed a mild degree of myocardial damage (<xref ref-type="fig" rid="fig5-0960327112454890">Figure 5(c)</xref>). However, rats pretreated with LCP 1.0 and 1.5 mg/kg exhibited a remarkable protection from deleterious effects of ISP as evidenced by reduced edema and absence of myocardial necrosis resembling to the normal myocardial histoarchitecture (<xref ref-type="fig" rid="fig5-0960327112454890">Figure 5(d)</xref> and (<xref ref-type="fig" rid="fig5-0960327112454890">e</xref>)).</p>
<fig id="fig5-0960327112454890" position="float">
<label>Figure 5.</label>
<caption>
<p>Light micrograph (hematoxylin and eosin; ×100) of the myocardium of the rat of (a) Sham group showing normal architecture of myocardium, (b) ISP-control group showing confluent focal necrosis of myofibrils and edema with infiltration of inflammatory cells and extravasations of red blood cells, (c) LCP 0.5 mg/kg + ISP showing slight myocardial necrosis and edema with inflammatory cells, (d) LCP 1.0 mg/kg + ISP showing lesser edema and myocardial necrosis, (e) LCP 1.5 mg/kg + ISP showing normal myocardial architecture with lessened necrosis and edema. LCP: lycopene; ISP: isoproterenol.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454890-fig5.tif"/>
</fig>
<table-wrap id="table5-0960327112454890" position="float">
<label>Table 5.</label>
<caption>
<p>Histopathological changes in myocardium of different experimental group.</p>
</caption>
<graphic alternate-form-of="table5-0960327112454890" xlink:href="10.1177_0960327112454890-table5.tif"/>
<table>
<thead>
<tr>
<th>Groups (treatment)</th>
<th>Myonecrosis</th>
<th>Inflammation</th>
<th>Edema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (Sham; vehicle)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>Group II (ISP control; vehicle + ISP)</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Group III (LCP 0.5 mg/kg)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>Group IV (LCP 1.0 mg/kg)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>Group V (LCP 1.5 mg/kg)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>Group VI (LCP 0.5 mg/kg + ISP)</td>
<td>+</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Group VII (LCP 1.0 mg/kg + ISP)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td>Group VIII (LCP 1.5 mg/kg + ISP)</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn17-0960327112454890">
<p>LCP: lycopene; ISP: isoproterenol; –: nil; +: mild; ++: moderate; +++: severe.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section20-0960327112454890">
<title>Discussion</title>
<p>The results of present study demonstrated the preventive effect of LCP in the animal model of ISP-induced MI. LCP exhibited its cardioprotective effects by improving cardiac function, reducing lipid peroxidation and strengthening the endogenous defense system of rat myocardium. Also, LCP pretreatment salvaged myocardium against ISP-induced myocardial necrosis as observed in histopathological examination.</p>
<p>Catecholamines are important regulators of myocardial metabolism and function. Excessive level of catecholamines have been known to cause cellular damage as observed in clinical conditions like angina, acute coronary insufficiency and MI.<sup>
<xref ref-type="bibr" rid="bibr32-0960327112454890">32</xref>
</sup> Generation of oxygen free radicals (OFRs) and ROS through auto-oxidation of catecholamines has been recognized as one of the important causative factors.<sup>
<xref ref-type="bibr" rid="bibr21-0960327112454890">21</xref>,<xref ref-type="bibr" rid="bibr22-0960327112454890">22</xref>
</sup> Numerous studies have demonstrated that ISP-induced oxidative ischemic injury of myocardium is associated with deterioration of hemodynamic and left ventricular contractile function.<sup>
<xref ref-type="bibr" rid="bibr21-0960327112454890">21</xref>,<xref ref-type="bibr" rid="bibr32-0960327112454890">32</xref>,<xref ref-type="bibr" rid="bibr33-0960327112454890">33</xref>
</sup> LCP pretreatment in present study have significantly prevented ISP-induced systolic and diastolic dysfunction as evidenced by improved SAP and DAP and subsequent increase in MAP, a marker of after load. LCP pretreatment also attenuated left ventricular dysfunction as evidenced by improved inotropic ((+)LVdP/dt) and lusitropic ((–)LVdP/dt) states of the heart, which was decreased after ISP administration. Furthermore, attenuation of ISP-induced rise in LVEDP, a surrogate marker of preload also demonstrates the recovery of ventricular function from ISP-induced myocardial damage. Favorable improvement in hemodynamic and left ventricular contractile function with LCP treatment indicates improved cardiac performance and recovery from ISP-induced MI.</p>
<p>Apart from hemodynamic and ventricular contractile function, several cardiospecific diagnostic marker enzymes like CK-MB isoenzyme and LDH are also present in myocardium which is used to predict pathological changes in the myocardium.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454890">2</xref>
</sup> These marker enzymes are leaked out into the extracellular fluids after myocardial injury due to disintegration of the cellular and subcellular compartments.<sup>
<xref ref-type="bibr" rid="bibr23-0960327112454890">23</xref>
</sup> Following administration of ISP, a significant decrease in myocardial CK-MB and LDH enzymes indicates their depletion from heart and delineates myocardial injury. However, rats pretreated with LCP showed a significant rise in myocardial enzymes; CK-MB isoenzyme and LDH demonstrate that LCP renders the cardiomyocytes less leaky due to membrane stabilization following reduced membrane lipid peroxidation.</p>
<p>As mentioned earlier, ISP-induced MI leads to the gradual loss of endogenous oxidant/antioxidant balance. The endogenous defense network constitutes enzymatic and nonenzymatic antioxidants; SOD, CAT, GSHPx and GSH which neutralizes OFRs and ROS in ischemic tissue.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454890">2</xref>
</sup> Decrease in the values of SOD and CAT following ISP administration indicate overwhelming of free radicals, which ensues oxidative damage to the myocardium. In previous studies, LCP has been reported as the most efficient biological carotenoid singlet oxygen quencher and shown to participate in first line of defense, maintained by SOD and CAT.<sup>
<xref ref-type="bibr" rid="bibr34-0960327112454890">34</xref>,<xref ref-type="bibr" rid="bibr35-0960327112454890">35</xref>
</sup> LCP in the present study prevented the decline of SOD and CAT in myocardium that is suggestive of its antioxidant and free radical scavenging activity in consonance to previous studies.<sup>
<xref ref-type="bibr" rid="bibr36-0960327112454890">36</xref>
</sup>
</p>
<p>In addition, the present study also showed a significant decrease in myocardial GSHPx enzyme and GSH, an endogenous antioxidant substrate following ISP administration. GSH has a direct antioxidant function by reacting with superoxide radicals, peroxy radicals and singlet oxygen followed by the formation of oxidized GSH and other disulfides and well known to replenish GSHPx, being its substrate.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112454890">3</xref>
</sup> Depletion of GSH from heart following ISP administration may have exceeded the ability of antioxidant enzymes to dismutate the radicals, resulting in oxidative damage of the myocardium. Reduction in the activities of GSH-dependent antioxidant enzyme, GSHPx following ISP administration might be corroborated to the decreased availability of its substrate, GSH. Reduced GSHPx activity causes accumulation of lipid peroxides and other oxidants which renders the cellular and subcellular membranes more susceptible to the oxidative damage. Pretreatment with LCP-prevented depletion of GSH and restored the GSHPx activity in myocardium of ISP-treated rats indicates its antiperoxidative activity in consonance to the previous study, which demonstrate its antiperoxidative activity against adriamycin-induced cardiotoxicity.<sup>
<xref ref-type="bibr" rid="bibr36-0960327112454890">36</xref>
</sup>
</p>
<p>By impairing antioxidant defense mechanisms, ISP renders the myocardium more susceptible to lipid peroxidation, an important oxidative degenerative pathogenic event in MI.<sup>
<xref ref-type="bibr" rid="bibr34-0960327112454890">34</xref>
</sup> In the present study, after ISP administration, the enhanced lipid peroxidation represented by MDA level might be due to compromised antioxidant defense, thus the free radical were not effectively neutralized and causes the myocardial damage. LCP pretreatment decreased the level of MDA, which might be due to enhanced activities of myocardial antioxidants and quenching of ROS and free radicals. Among naturally occurring carotenoids, LCP has the strongest ability to scavenge free radicals, being 10-fold, 47-fold and 100-fold more effective in quenching singlet oxygen than α-tocopherol, β-carotene and vitamin E, respectively.<sup>
<xref ref-type="bibr" rid="bibr34-0960327112454890">34</xref>
</sup> Among the various defense mechanisms, LCP is most likely to be involved in the scavenging of two of the ROS, singlet molecular oxygen and peroxy radicals, even at low-oxygen tension.<sup>
<xref ref-type="bibr" rid="bibr37-0960327112454890">37</xref>
</sup> In the present study, ISP-induced myocardial ischemia invoked a condition of low oxygen availability consequent to reduced blood supply, where this unique property of LCP to quench free radicals at low oxygen tension might contribute to the afforded cardioprotection.<sup>
<xref ref-type="bibr" rid="bibr37-0960327112454890">37</xref>,<xref ref-type="bibr" rid="bibr38-0960327112454890">38</xref>
</sup>
</p>
<p>The protective effects of LCP on myocardial histoarchitecture were further confirmed by light microscopic examination. Several studies suggested that ISP produces histopathological lesions similar to those of coagulative myocytolysis or myofibrillar degeneration, which is one of the signs of acute MI in man.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112454890">18</xref>
</sup> Subsequent to ISP administration, significant myonecrosis, edema and infiltration of inflammatory cells were observed in the myocardium of ISP control rats. However, rats pretreated with LCP have shown resistance toward myocardial damage by reduced necrosis and edema. LCP-treated groups show preservation of structural integrity with predominantly normal cardiomyocytes morphology at all three doses and with no sign of leukocyte infiltration. Increased CK-MB and LDH in heart further supports this observation suggesting the preservation of membrane integrity. Improved antioxidant status and inhibition of lipid peroxidation might have attributed to the myocardial salvage and morphological recoup of the myocardium against ISP-induced myocardial necrosis. LCP per se treated rats showed normal cardiac myofibers without pathological changes, therefore indicating that LCP is safe to cardiomyocytes and does not render any adverse effects on myocardium.</p>
<p>Furthermore, the protective effect of LCP against the myocardial membrane damage can also be explained based upon its lipophilic nature.<sup>
<xref ref-type="bibr" rid="bibr39-0960327112454890">39</xref>
</sup> It is presumed that LCP similar to other lipophilic agents such as vitamin E, antipyrine, nifedipine and β-blocking drugs intercalate into the lipid matrix and impart stabilization to myocardial cell membranes pertinent to the degree of their lipophilicity.<sup>
<xref ref-type="bibr" rid="bibr40-0960327112454890">40</xref>
</sup> Thus, it is possible that LCP may also render resistance and impart stabilization to the myocardial cell membranes by extending the viability from necrotic damage.</p>
<p>To conclude, present study findings shows that LCP treatment maintained the antioxidant levels, preserved histology of myocardium and improved cardiac performance following ISP administration. The results of this study suggest that LCP may serve as an adjunct in prophylaxis and treatment in delaying the progression of MI.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Mr BM Sharma for his technical assistance in the course of study.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327112454890">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112454890">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruff</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Braunwald</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>The evolving epidemiology of acute coronary syndromes</article-title>. <source>Nat Rev Cardiol</source> <year>2011</year>; <volume>8</volume>: <fpage>140</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112454890">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhalla</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Elmoselhi</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Hata</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Makino</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Status of myocardial antioxidants in ischemia-reperfusion injury</article-title>. <source>Cardiovas Res</source> <year>2000</year>; <volume>47</volume>: <fpage>446</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112454890">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Upaganlawar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zalawadia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Balaraman</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Cardioprotective effect of melatonin against isoproterenol-induced myocardial infarction in rats: a biochemical, electrocardiographic and histoarchitectural evaluation</article-title>. <source>Eur J Pharmacol</source> <year>2010</year>; <volume>644</volume>: <fpage>160</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112454890">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tinkel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hassanain</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Khouri</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms</article-title>. <source>Cardiol Rev</source> <year>2012</year>; <volume>20</volume>: <fpage>77</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112454890">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visioli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Borsani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Claudio</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Diet and prevention of coronary heart disease: the potential role of phytochemicals</article-title>. <source>Cardiovasc Res</source> <year>2000</year>; <volume>47</volume>: <fpage>419</fpage>–<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112454890">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hearse</surname>
<given-names>DJ.</given-names>
</name>
</person-group> <article-title>Prospects for antioxidant therapy in cardiovascular medicine</article-title>. <source>Am J Med</source> <year>1991</year>; <volume>91</volume>: <fpage>118S</fpage>–<lpage>121S</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112454890">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hertog</surname>
<given-names>MGL</given-names>
</name>
<name>
<surname>Feskens</surname>
<given-names>EJM</given-names>
</name>
<name>
<surname>Hollam</surname>
<given-names>PCH</given-names>
</name>
<name>
<surname>Katan</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Kromhout</surname>
<given-names>D.</given-names>
</name>
</person-group> <article-title>Dietary antioxidant flavonoids and risk of coronary heart diseases. The Zutphen Elderly Study</article-title>. <source>Lancet</source> <year>1993</year>; <volume>342</volume>: <fpage>1007</fpage>–<lpage>1020</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112454890">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ignarro</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Balestrieri</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Nutrition, physical activity, and cardiovascular disease: an update</article-title>. <source>Cardiovasc Res</source> <year>2007</year>; <volume>73</volume>: <fpage>326</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112454890">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krinsky</surname>
<given-names>NI</given-names>
</name>
</person-group>. <article-title>Overview of lycopene, carotenoids, and disease prevention</article-title>. <source>Proc Soc Exp Biol Med</source> <year>1998</year>; <volume>218</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112454890">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clinton</surname>
<given-names>SK</given-names>
</name>
</person-group>. <article-title>Lycopene: chemistry, biology, and implications for human health and disease</article-title>. <source>Nutr Rev</source> <year>1998</year>; <volume>1</volume>: <fpage>35</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112454890">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bansal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Ojha</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Nandave</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mittal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kumari</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Cardioprotective effect of lycopene in the experimental model of myocardial ischemia-reperfusion injury</article-title>. <source>Mol Cell Biochem</source> <year>2006</year>; <volume>289</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112454890">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anjos Ferreira</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Rocha</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Placido Ladeira</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Favero Salvadori</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Oliveira Nascimento</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group> <article-title>Effect of lycopene on doxorubicin-induced cardiotoxicity: an echocardiographic, histological and morphometrical assessment</article-title>. <source>Basic Clin Pharmacol Toxicol</source> <year>2007</year>; <volume>101</volume>: <fpage>16</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112454890">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Tzu</surname>
<given-names>NH</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Sheu</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>A potent antioxidant lycopene affords neuroprotection against microglia activation and focal cerebral ischemia in rats</article-title>. <source>In Vivo</source> <year>2004</year>; <volume>18</volume>: <fpage>351</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112454890">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbaraly</surname>
<given-names>NT</given-names>
</name>
<name>
<surname>Faure</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gourlet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Favier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Berr</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Plasma carotenoid levels and cognitive performance in an elderly population: results of the EVA study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source> <year>2007</year>; <volume>62</volume>: <fpage>308</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112454890">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohlmeier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kark</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Gomez-Gracia</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>BC</given-names>
</name>
<name>
<surname>Steck</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kardinaal</surname>
<given-names>AFM</given-names>
</name>
<etal/>
</person-group> <article-title>Lycopene and myocardial infarction risk in the EURAMIC Study</article-title>. <source>Am J Epidemiol</source> <year>1997</year>; <volume>146</volume>: <fpage>618</fpage>–<lpage>626</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112454890">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arab</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Steck</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Lycopene and cardiovascular disease</article-title>. <source>Am J Clin Nutr</source> <year>2000</year>; <volume>71</volume>: <fpage>1691S</fpage>–<lpage>1695S</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112454890">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riccioni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mancini</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Di Ilio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bucciarelli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>D'Orazio</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Protective effect of lycopene in cardiovascular disease</article-title>. <source>Eur Rev Med Pharmacol Sci</source> <year>2008</year>; <volume>12</volume>: <fpage>183</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr18-0960327112454890">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gallus</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Negri</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Parpinel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>La Vecchia</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Dietary intake of carotenoids and retinol and the risk of acute myocardial infarction in Italy</article-title>. <source>Free Radic Res</source> <year>2006</year>; <volume>40</volume>: <fpage>659</fpage>–<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr19-0960327112454890">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Khoo</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Ismail</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Rajab</surname>
<given-names>NF</given-names>
</name>
</person-group>. <article-title>Revealing the power of natural red pigment lycopene</article-title>. <source>Molecules</source> <year>2010</year>; <volume>15</volume>: <fpage>959</fpage>–<lpage>987</lpage>.</citation>
</ref>
<ref id="bibr20-0960327112454890">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rona</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Catecholamine cardiotoxicity</article-title>. <source>J Mol Cell Cardiol</source> <year>1985</year>; <volume>17</volume>: <fpage>291</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr21-0960327112454890">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ojha</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Nandave</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Narang</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dinda</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Arya</surname>
<given-names>DS</given-names>
</name>
</person-group>. <article-title>Chronic administration of <italic>Tribulus terrestris</italic> Linn extract improves cardiac function and attenuates myocardial infarction in rats</article-title>. <source>Int J Pharmacol</source> <year>2008</year>; <volume>4</volume>: <fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr22-0960327112454890">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harada</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Futaka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Miwa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kaneta</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fukushima</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Effect of KRN 2391, a novel vasodilator, on various experimental angina models in rats</article-title>. <source>Jpn J Pharmacol</source> <year>1993</year>; <volume>63</volume>: <fpage>35</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr23-0960327112454890">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mladenka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hrdina</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bobrovová</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Semecký</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vávrová</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Holecková</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Cardiac biomarkers in a model of acute catecholamine cardiotoxicity</article-title>. <source>Hum Exp Toxicol</source> <year>2009</year>; <volume>28</volume>: <fpage>631</fpage>–<lpage>640</lpage>.</citation>
</ref>
<ref id="bibr24-0960327112454890">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maron</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Depierre</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Manmerik</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Level of glutathione, glutathione reductase and glutathione-s-transferase activity in rat lung and liver</article-title>. <source>Biochem Biophys Acta</source> <year>1979</year>; <volume>82</volume>: <fpage>67</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr25-0960327112454890">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohkawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ohishi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yagi</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Assay of lipid peroxide in animal tissue by thiobarbituric acid reaction</article-title>. <source>Ann Biochem</source> <year>1979</year>; <volume>95</volume>: <fpage>351</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr26-0960327112454890">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Misra</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Fridovich</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>The oxidation of phenylhydrazine: superoxide and mechanisms</article-title>. <source>Biochem</source> <year>1976</year>; <volume>15</volume>: <fpage>681</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr27-0960327112454890">
<label>27</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Aebi</surname>
<given-names>H.</given-names>
</name>
</person-group> <article-title>Catalase</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Bergmayer</surname>
<given-names>HE</given-names>
</name>
</person-group> (ed) <source>Methods of enzymatic analysis</source>. <edition>2nd ed</edition>. <volume>Vol 2</volume>. <publisher-name>Academic Press</publisher-name>, <publisher-loc>New York</publisher-loc>, <year>1974</year>, pp. <fpage>213</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr28-0960327112454890">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paglia</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Valentine</surname>
<given-names>WN</given-names>
</name>
</person-group>. <article-title>Studies on the quantitative and qualitative characterization of erythrocyte peroxidase</article-title>. <source>J Lab Clin Med</source> <year>1967</year>; <volume>2</volume>: <fpage>158</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr29-0960327112454890">
<label>29</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Lamprecht</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Stan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Weisser</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Heinz</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Determination of creatine phosphate and adenosine triphosphate with creatine kinase</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Bergmeyer</surname>
<given-names>HU</given-names>
</name>
</person-group> (ed) <source>Methods of enzymatic analysis</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Academic Press</publisher-name>, <year>1974</year>, <fpage>1776</fpage>–<lpage>1778</lpage>.</citation>
</ref>
<ref id="bibr30-0960327112454890">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabaud</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Wroblewski</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Calorimetric measurements of lactic dehydrogenase activity of body fluids</article-title>. <source>Am J Clin Pathol</source> <year>1958</year>; <volume>3</volume>: <fpage>234</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr31-0960327112454890">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowry</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Rosebrough</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Farr</surname>
<given-names>AI</given-names>
</name>
</person-group>. <article-title>Protein measurements with the folin-phenol reagent</article-title>. <source>J Biol Chem</source> <year>1951</year>; <volume>193</volume>: <fpage>265</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr32-0960327112454890">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeager</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Iams</surname>
<given-names>SG</given-names>
</name>
</person-group>. <article-title>The hemodynamics of isoproterenol-induced cardiac failure in the rat</article-title>. <source>Cir Shock</source> <year>1981</year>; <volume>8</volume>: <fpage>151</fpage>–<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr33-0960327112454890">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tappia</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Heta</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dhalla</surname>
<given-names>NS</given-names>
</name>
</person-group>. <article-title>Role of oxidative stress in catecholamine-induced changes in cardiac sarcolemmal Ca<sup>2+</sup> transport</article-title>. <source>Arch Biochem Biophys</source> <year>2001</year>; <volume>377</volume>: <fpage>85</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr34-0960327112454890">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Candeias</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Bramley</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Rice-Evans</surname>
<given-names>CA</given-names>
</name>
</person-group>. <article-title>Antioxidant activities of carotenes and xanthophylls</article-title>. <source>FEBS Lett</source> <year>1996</year>; <volume>384</volume>: <fpage>240</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr35-0960327112454890">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Mascio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sies</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Lycopene as the most effective biological carotenoid singlet oxygen scavenger</article-title>. <source>Arch Biochem Biophys</source> <year>1989</year>; <volume>274</volume>: <fpage>532</fpage>–<lpage>538</lpage>.</citation>
</ref>
<ref id="bibr36-0960327112454890">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Atessahin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sahna</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Karahan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ozer</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity</article-title>. <source>Toxicology</source> <year>2006</year>; <volume>218</volume>: <fpage>164</fpage>–<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr37-0960327112454890">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stahl</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Sies</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Antioxidant activity of carotenoids</article-title>. <source>Mol Aspects Med</source> <year>2003</year>; <volume>24</volume>: <fpage>345</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr38-0960327112454890">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodall</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Weesie</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Britton</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Oxidation of carotenoids by free radicals: relationship between structure and reactivity</article-title>. <source>Biochim Biophys Acta</source> <year>1997</year>; <volume>1336</volume>: <fpage>33</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr39-0960327112454890">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Britton</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Structure and properties of carotenoids in relation to function</article-title>. <source>FASEB J</source> <year>1995</year>; <volume>9</volume>: <fpage>1551</fpage>–<lpage>1558</lpage>.</citation>
</ref>
<ref id="bibr40-0960327112454890">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cruickshank</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Dweyer</surname>
<given-names>GN.</given-names>
</name>
</person-group> <article-title>β-Blocker brain concentrations in man</article-title>. <source>Eur J Clin Pharmacol</source> <year>1985</year>; <volume>28</volume>: <fpage>21</fpage>–<lpage>23</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>